Gemcovac-19 is built on a platform that can be tweaked to make vaccines for future pandemics, and can be deployed in lower income countries as the primary Covid-19 vaccine
Gennova Biopharmaceuticals' mRNA vaccine may just be a tad bit late to the vaccine party in the country
In India’s Covid-19 vaccination race, Gennova Biopharmaceuticals may just be a little late. After all, the country has already completed 198 crore vaccinations, among the highest globally. Of these, 101 crore people have received their first vaccine dose, while 92 crore people have received both. This is nearly 70 percent of India’s 138 crore population.
Covishield, manufactured by Serum Institute of India (SII) in partnership with AstraZeneca, accounted for some 80 percent of doses. Covaxin, manufactured by Hyderabad-based Bharat Biotech, accounted for a significant part of the rest; followed by Biological E’s, Corbevax, and Russia’s Sputnik V.